Two-Pronged attack on rare blood cancers shows promise in trial
NCT ID NCT01787487
Summary
This study tested whether combining two existing drugs, ruxolitinib and azacytidine, could better control certain rare blood cancers. It involved 121 adults with myelofibrosis or similar conditions where the bone marrow doesn't work properly. The goal was to see if using both drugs together was safe and more effective at shrinking the disease and improving symptoms than previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.